Document is current
Any future updates will be listed below
-
Authors
Schlesinger, Naomi https://orcid.org/0000-0002-1558-1202
Pérez-Ruiz, Fernando https://orcid.org/0000-0002-5268-1894
Lioté, Frédéric https://orcid.org/0000-0003-4419-0726
- License Information
-
More Information
Article History
Accepted: 18 July 2023
First Online: 8 September 2023
Competing interests
: N.S. declares that she has received a grant from Olatec and has been on advisory boards and acted as a consultant for ANI, Horizon Pharma, Novartis, Protalix and SOBI. F.P.-R. declares that he is an adviser for Anlylam, Arthriti and Protalix; a speaker for Menarini Central America; a member of Data and Safety Monitoring Board (DMSB) for Selecta/SOBI; does editorial work for Springer Healthcare, Wolters-Kluwer, Exploration Publications and the Spanish Foundation for Rheumatology; and has received grants from the Cruces Rheumatology Association. F.L. declares that he has been on advisory boards for Horizon Pharma, Novartis France and Olatec; is a member of DMSB for Olatec; does editorial work for Elsevier; is a CME speaker for Mayoly-Spindler, Menarini Central America and Novartis; and has received unrestricted educational grants from Horizon Pharma, Mayoly-Spindler, Novartis, Olatec and SOBI for the European Crystal Network workshops.
